CPL Biologicals breaks ground on Indian vaccine manufacturing facility
CPL Biologicals, the new joint venture between Cadila Pharmaceuticals in India and US clinical-stage biotechnology company Novavax, has begun construction of a state-of-the-art manufacturing facility that will be used to produce pandemic and seasonal influenza vaccines.
CPL Biologicals, the new joint venture between Cadila Pharmaceuticals in India and US clinical-stage biotechnology company Novavax, has begun construction of a state-of-the-art manufacturing facility that will be used to produce pandemic and seasonal influenza vaccines.
The 25,000 ft2 facility is expected to be operational within four months and should be capable of producing more than 60 million doses annually at full capacity.
CPL Biologicals will utilise Novavax's virus-like particle (VLP) vaccine technology to produce commercial-scale quantities of VLP-based influenza vaccines using Novavax's innovative disposable manufacturing solution. The facility will also be used to produce other novel vaccines being developed by CPL Biologicals, based on Novavax's VLP vaccine technology.
"This new facility is being 100% supported financially by our partner, Cadila Pharmaceuticals," said John Trizzino, senior vice president, international and government alliances for Novavax and interim ceo of CPL Biologicals. "We anticipate creating sufficient capacity for CPL Biologicals to sell influenza vaccines in India and at the same time become a potential supplier to Novavax for sale of vaccines in other markets where Novavax maintains complete commercial rights.
"We believe this model will show how an efficient and scalable vaccine platform can help address the growing demand for pandemic and seasonal influenza vaccines. Moreover, the construction of this manufacturing facility is consistent with Novavax's strategy to establish regional partnerships and regional manufacturing capabilities that allow our VLP influenza vaccines to be licensed, manufactured and sold throughout the world."